The first 60 days: Synovial sarcoma
Synovial sarcoma is a young person's sarcoma driven by a single fusion gene, SS18-SSX, that scrambles how genes are switched on. It is treated with surgery, radiotherapy and ifosfamide-based chemotherapy, and in 2024 it became the first solid tumour with an approved engineered T-cell receptor therapy. Below, week by week, is what OnCo's record of Synovial sarcoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Localised.
- Medical oncologistNamed in the standard of care for: Localised, Advanced, first line, Advanced, HLA-A*02 and MAGE-A4-positive.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Localised.
- Transplant and cell therapy teamNamed in the standard of care for: Advanced, HLA-A*02 and MAGE-A4-positive.
- Palliative and supportive care teamNamed in the standard of care for: Localised, Advanced, first line.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Wide resection with pre- or postoperative radiotherapy; neoadjuvant or adjuvant ifosfamide-doxorubicin for large high-risk tumours.
Ifosfamide-based chemotherapy, doxorubicin; pazopanib or trabectedin later.
Afamitresgene autoleucel after chemotherapy; NY-ESO-1 TCR therapy in trials.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example SS18-SSX fusion, MAGE-A4 and NY-ESO-1 expression with HLA-A*02 typing, Size over 5 cm and poorly differentiated component), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Monophasic synovial sarcoma, Biphasic synovial sarcoma, Poorly differentiatedsynovial sarcoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised
- For my situation (localised), which of the standard options do you recommend and why?Guideline options include: Wide resection with pre- or postoperative radiotherapy; neoadjuvant or adjuvant ifosfamide-doxorubicin for large high-risk tumours.
- Am I a candidate for Ifosfamide, Doxorubicin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced, first line
- For my situation (advanced, first line), which of the standard options do you recommend and why?Guideline options include: Ifosfamide-based chemotherapy, doxorubicin; pazopanib or trabectedin later.
- Am I a candidate for Ifosfamide, Doxorubicin, Pazopanib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced, HLA-A*02 and MAGE-A4-positive
- For my situation (advanced, hla-a*02 and mage-a4-positive), which of the standard options do you recommend and why?Guideline options include: Afamitresgene autoleucel after chemotherapy; NY-ESO-1 TCR therapy in trials.
- Am I a candidate for Afamitresgene autoleucel, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Letetresgene autoleucel?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “TCR therapy needs a matching HLA type and antigen, excluding most patients”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Late lung metastases years after treatment”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Synovial sarcoma: the full pageSynovial sarcoma is a young person's sarcoma driven by a single fusion gene, SS18-SSX, that scrambles how genes are switched on. It is treated with surgery, radiotherapy and ifosfamide-based chemotherapy, and in 2024 it became the first solid tumour with an approved engineered T-cell receptor therapy.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.